American Premium Water (OTC: HIPH) is a diversified luxury consumer products company focused on businesses in the health and beauty and biotech sectors. The company is focused on harnessing the powers of Nano technologies paired without cannabidiol (CBD) to treat health disorders and enhance quality of life. The company’s portfolio includes the LALPINA Hydro and LALPINA CBD brands (www.lalpinahydrocbd.com), Gents (www.gentsco.com), Vanexxe (www.vanexxe.com) plant + body essentials (www.plantbodyessentials.com).
The company recently announced that it has begun production on the first run of proprietary nano-infused products through its distribution agreement with BioHealth Water Inc. (“BioHealth Water”), a wholly owned subsidiary of Alset International Limited (SGX:40V) (“Alset”). The initial production run marks the beginning of the Company’s efforts to sell its aerosolized sanitizing machines, in addition to its two new products utilizing its proprietary Hydro Nano technology: Nano Energy Water and Nitrous Oxide Shots. The products are in process of application for product distribution in Malaysia, Hong Kong, Taiwan, Singapore, USA and Canada.
Ryan Fishoff, CEO of American Premium Water, commented, “I am excited to announce the beginning of production for our new products with our new partner in BioHealth Water. This first run will get the products into the hands of distributors across the Pacific Rim (North America & Asia). We are only scratching the surface of the potential that we have with BioHealth Water, and I look forward to receiving feedback from our distributors as we prepare for full scale production later this year. Our plans to increase the volume of distribution alongside various other initiatives that we intend to achieve in the remaining quarter of 2020 will set a firm platform for us to move full steam into 2021. As I have been emphasizing over the years, I believe this partnership highlights the value of the Company’s Hydro Nano technology. We are exploring even more ways to unlock value from this technology, and I look forward to sharing these developments with shareholders in the coming weeks and months.”
Cannagistics, Inc. (OTC: CNGT) is a U.S. corporation that operates both general and specialty 3PLs (3rd party logistics) with a focus on supply chain management, reverse logistics, warehousing, and transportation, and currently developing industry-specific technology platforms. Global3PL (Ontario, Canada) is our general commodities operation, with warehouses in Canada and the U.S. that provide monthly and just-in-time inventory, pick and ship, custom house brokerage, as well as international freight forwarding, expedited and deferred air, local, regional, and North American consumer household pickup and delivery, less-than-truckload (“LTL”), truckload (TL), Cannagistics, Inc. (our Canadian subsidiary) is a cannabis-specific logistics company aimed at streamlining the fragmented cannabis marketplace. The first Canadian company to obtain its own bonded warehouse license for cannabis, we’re also developing the most robust supply chain technology platform specifically for the cannabis ecosystem — to tap the enormous opportunities in the emerging global cannabis marketplace With an intent to solve pain points, we’ll use technology to streamline the complexities of coordinating compliance (state by state and country by country), logistics, international clearances, information, and product shelf-life tracking, powered by services by our knowledge-based operations team.
Enzolytics, Inc. (OTC: ENZC) is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. The Company is committed to creating drugs for the better health of mankind. ENZC’s flagship compound ITV-1 is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from major neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use today. IPF has not shown to be subject to viral resistance and is cost effective.
BioElectronics Corp (OTC: BIEL) is an electroceutical (electrical stimulation device) company that commercializes pulsed shortwave therapy (PSWT) to treat and manage a variety of chronic neurological disorders. PSWT provides high-frequency, pulsed electromagnetic field (EMF) neuromodulation in the form of an affordable, wearable and non-invasive device. Central sensitization (CS) is widely accepted as the physiological explanation for many neurological disorders such as chronic musculoskeletal pain, postoperative pain, peripheral neuropathy, migraine headaches, overactive bladder etc. These neurological conditions arise as a result of “hypersensitization” of the central nervous system, originally triggered by, but not necessarily sustained by constant peripheral nerve activity (e.g. injury). BioElectronics’ PSWT technology mitigates this hypersensitivity by modulating peripheral nerve activity in the area of application. For conditions such as musculoskeletal pain, successful treatment manifests as pain relief, while for non-painful conditions such as overactive bladder it manifests as decreased urge incontinence. Dr. Ken McLeod, Ph.D., a world-renowned bioelectromagnetics researcher at the State University of New York – Binghamton, provides a short video explanation on the mechanism of action at: http://www.actipatch.com/pharmacy The market for treating neurological disorders is significantly larger than that for diabetes, heart disease and cancer combined – 1 in 5 adults worldwide.